thrombotic microangiopathies (TMAs) in patients co-administered sirolimus and calcineurin inhibitors (CNIs) or on sirolimus monotherapy.

Case Report: We present the case of a 67 year old male, who received a living unrelated renal transplant in August 2007 (3/6 HLA mismatch) for IgA nephropathy. Early post transplant course was complicated by biopsy proven BK virus associated nephropathy (2008) and multiple non-melanoma skin cancers. Tacrolimus was continued due to borderline rejection after its withdrawal in 2009. Mycotic was replaced with azathioprine in Feb 2012 for diarrhoea. Azathioprine was changed to sirolimus in January 2013 due to recurrent skin cancers and cytopenic changes of BK virus on urine analysis.

The patient presented with a generalised seizure followed by right hemiparesis secondary to imaging confirmed transverse sinus thrombosis in February 2013, with no prior history of thrombosis. He was treated with levetiracetam and anticoagulation, and sirolimus was replaced by azathioprine. Allograft function did not deteriorate, nor did he demonstrate any significant proteinuria or post-transplant erythrocytosis. The patient achieved a good functional outcome without residual neurological deficits.

Conclusion: Sirolimus induced thrombosis should be considered in transplant patients presenting with CSVT, and use of this agent should be cautioned in patients with pre-existing thrombotic tendencies.

CONFLICTS OF INTEREST

A PRAGMATIC TRIAL OF A POLYPILL-BASED STRATEGY TO IMPROVE ADHERENCE TO INDICATED PREVENTIVE TREATMENTS AMONG PEOPLE AT HIGH CARDIOVASCULAR DISEASE RISK

A Cass, A Patel, A Rodgers

The polypill formulations used in this study have been developed and provided free of charge by Dr Reddy’s Laboratories, Hyderabad, India.

A RANDOMISED, CONTROLLED TRIAL OF EXIT SITE APPLICATION OF MEDIHONEY FOR THE PREVENTION OF CATHETER-ASSOCIATED INFECTIONS IN PD PATIENTS – HONEYPOT STUDY

D Johnson, S Badve, E Pascoe, E Beller, A Cass, C Clark, J de Zoya, S McTaggart, N Ibel, A Morrish

Dj is a consultant for Baxter Healthcare Pty Ltd and has previously received research funds from this company. He has also received speakers’ honoraria and research grants from Fresenius Medical Care. He has previously been a consultant to Gambro Pty Ltd and was the recipient of a Gambro Research Grant which partly funded the HONEYPOT trial. NI, CC, and Dj received a Baxter Healthcare Renal Discoveries Extramural Program Grant which partly funded the HONEYPOT trial. Dj is an International Society of Peritoneal Dialysis Councilor and is a current recipient of a Queensland Government Health Research Fellowship.

ACUTE KIDNEY INJURY, ANALGESIC NEPHROPATHY AND TOXIN-MEDIATED KIDNEY INJURY IN AN AUSTRALIAN CHRONIC KIDNEY DISEASE (CKD) COHORT

A Mallett, A Salisbury, Z Wang, HG Healy, WE Hoy

AM is supported by a RBWH Foundation scholarship and Queensland Health. CKD.QLD is supported by Amgen, NHMRC Australia (Australian Fellowship: Hoy), the Colonial Foundation of Australia, Queensland Health (in kind) and Roche.

ALPORT SYNDROME AND THIN BASEMENT MEMBRANE NEPHRPATHY IN THE QUEENSLAND CHRONIC KIDNEY DISEASE (CKD) REGISTRY

A Mallett, A Salisbury, Z Wang, HG Healy, WE Hoy

AM is supported by a RBWH Foundation scholarship and Queensland Health. CKD.QLD is supported by Amgen, NHMRC Australia (Australian Fellowship: Hoy), the Colonial Foundation of Australia, Queensland Health (in kind) and Roche.

ANALYSIS OF THE COST-EFFECTIVENESS OF SWITCHING FROM SEVELAMER HYDROCHLORIDE TO LANTHANUM CARBONATE MONOTHERAPY: APPLICATIONS FOR AUSTRALIAN COSTS

R Agnew, R Wilson, M Keith, J Brian Copely

RA is an employee of Shire Australia and stockholder of Shire Development LLC.

APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) PROMOTES RENAL FIBROSIS AND APOPTOSIS IN THE OBSTRUCTED KIDNEY

F Y Ma, D Breckenridge, D Nikolic-Paterson

DB is an employee of Gilead Science. Gilead provided financial support for this study. DN-P is a consultant for Gilead.

AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE IN AN AUSTRALIAN CHRONIC KIDNEY DISEASE (CKD) POPULATION

A Mallett, A Salisbury, Z Wang, HG Healy, A Salisbury, WE Hoy

AM is supported by a RBWH Foundation scholarship and Queensland Health. CKD.QLD is supported by Amgen, NHMRC Australia (Australian Fellowship: Hoy), the Colonial Foundation of Australia, Queensland Health (in kind) and Roche.

BLOCKING THE NADPH OXIDASE NOX4 ACTIVITY PROVIDES RENOPROTECTION IN LONG TERM DIABETIC NEPHROPATHY

J Jha, SP Gray, K Wingler, C Syndralewicz, F Heitz, ME Cooper, H HHW Schmidt, KJ Jandeleit-Dahm

CS and FF are paid employees and own shares of GenKyoTex SA, Geneva, Switzerland. All remaining authors report no conflicts.

BLOCKADE OF SLEEN TYROSINE KINASE (SYK) INHIBITS ANTIBODY-MEDIATED REJECTION IN RAT RENAL ALLOGRAFTS

S Rameswar, F Ma, G Tesch, N Woodward, Y Han, K Bleese, W Mulley, J Kanellis, D Nikolic-Paterson

KB and EN-P are employees of Celgene.

CALCIPROTEIN-ASSOCIATED FETUIN-A CONCENTRATION IS ASSOCIATED WITH ALL-CAUSE MORTALITY IN PATIENTS WITH PRE-TRANSPLANT EPIDEMIOLOGY

E Smith, L Tomlinson, M Ford, E Bodenham, L McMahon, C Rajkumar, S Holt

ES, LM and SH have received research funding from Amgen and Baxter. ES has received honoraria from Shire. SH has received honoraria from Amgen, Baxter, Gilead and Shire.

CHRONIC KIDNEY DISEASE (CKD) IS NOT RENAL REPLACEMENT THERAPY (RRT): THE CKD.QLD REGISTRY DATASET

H Healy, A Salisbury, Z Wang, A Mallett, S Huynh, A Salisbury, T Mohandas, P Sanghi, D Heffernan, R Fassett, W Hoy

CKD.QLD is supported by Amgen, NHMRC Australia (Australian Fellowship: Hoy), the Colonial Foundation of Australia, Queensland Health (in kind) and Roche.

CHRONIC KIDNEY DISEASE (CKD) PATIENT OUTCOMES: A LONGITUDINAL REPORT FROM THE CKD.QLD REGISTRY

A Salisbury, A Mallett, Z Wang, H G Healy, S Huynh, S Smith, D Heffernan, W E Hoy

CKD.QLD is supported by Amgen, NHMRC Australia (Australian Fellowship: Hoy), the Colonial Foundation of Australia, Queensland Health (in kind) and Roche.

CKD PATIENT PROFILES FROM A REGIONAL QUEENSLAND HEALTH RENAL CLINIC AND OUTCOMES AFTER ONE YEAR. CKD.QLD REGISTRY

R Fassett, A Salisbury, C Banney, R Chetian, A Salisbury, Z Wang, W Hoy

RF is supported by Queensland Health, and via CKD.QLD, by Amgen, NHMRC Australia (Australian Fellowship: Hoy), the Colonial Foundation of Australia, Queensland Health and Roche.

CNI-TO-EVEROLIMUS CONVERSION IN RENAL TRANSPLANT RECIPIENTS WITH LOW IMMUNOLOGICAL RISK: IMPROVED OR MAIN- TAINED GFR AFTER 2.5 YEARS

H Gock, M Mathew

HG has received honoraria from Novartis in 2012 and 2013 for presentations at sponsored meetings.

END-STAGE KIDNEY DISEASE – SUPPORTING THE TREATMENT OPTION DECISION MAKING PROCESS

D Fortnum, I Smolomogov, L Kairaitis

Decision aid meetings were funded by Baxter with an unrestricted educational grant.
FETUIN-A-CONTAINING CALCI PROTEIN PARTICLES IN PERITONEAL DIALYSIS FLUID
E Smith, A Kent, L McMahon, T Hewitson, S Holt
ES, LM and SH have received research funding from Amgen and Baxter. ES has received honoraria from Shire. SH has received honoraria from Amgen, Baxter, Gilead and Shire.

"I Don’t Like What I Read About Chronic Kidney Disease, I Might As Well Just Go Get A Gun And Shoot Myself": Focus Group Study of Patients with Early Stage Chronic Kidney Disease
PA Lopez-Vargas, A Tong, R KS Phoon, SJ Chadban, Y Shen, JC Craig
PL-V is supported by a National Health and Medical Research Council Scholarship (APP1017160). AT is supported by a National Health and Medical Research Council Fellowship (ID 1037162).

PLASMA CYSTATIN C IS ELEVATED IN THE ABSENCE OF ACUTE KIDNEY INJURY FOLLOWING CISPLATIN WITH CONTEMPORARY ANTIEMETICS
T Pianta, M Chin, P Peake, N Buckley, J Pickering, Z Endre
TP acknowledges the financial support of the Jacquot Research Entry Scholarship and a University of New South Wales Australian Postgraduate Award. ZE has received research and travel support from Alere and Abbott.

PYRROLIDINE DITHIOCARBAMATE ATTENUATES KIDNEY ENLARGEMENT IN EXPERIMENTAL POLYCYSTIC KIDNEY DISEASE
Michelle Ta, P Rao, M Korogoorkar, S Foster, A Pedato, D Harris, G Rangan
MT was supported by the Michael Stern Polycystic Kidney Disease Research Fellowship, and an Australian Postgraduate Award (University of Sydney). Research work of the authors was supported by the NHMRC (Grants no. 632647 and 457575).

RENOPROTECTION WITH SGLT2 INHIBITION
Muralikrishna Gangadharan Komala, S Gross, K Pegg, C Huang, J Chen, A Mather, C Pollock, U Panchapakesan
The study has been partly supported by Boehringer Ingelheim and the study drug has been provided by them. Boehringer Ingelheim had no role in study design and analysis.

SHORT AND LONG TERM BIOLOGICAL VARIATION OF HIGH SENSITIVITY TROPOIN T (HS-TNT) AND N-TERMINAL B-TYPE NATRIURETIC PEPTIDE (NT-PROBNP) IN THE STABLE DIALYSIS POPULATION
M Fahim, A Hayen, A Coburn, G Dimeski, D Johnson, J Craig, A Rita Horvath, S Campbell, C Hawley
MF received unrestricted research support from Roche Diagnostics and Fresenius Medical Care

THE DEVELOPMENT AND GROWTH OF CKD.QLD: A FOUR YEAR JOURNEY
S Krishna Venuthurupalli, A Salisbury, W E Hoy, H G Healy, R G Fassett, A Salisbury
SV is completing his PhD via CKD.QLD which is supported by Amgen, NHMRC Australia (Australian Fellowship: Hoy), the Colonial Foundation of Australia, Queensland Health (in kind) and Roche.

URINARY CLUSTERIN PREDICTS GRAFT RECOVERY WITHIN FOUR HOURS OF KIDNEY TRANSPLANTATION
T Pianta, P Peake, N Buckley, M Kelleher, J Pickering, Z Endre
TP acknowledges the financial support of the Jacquot Research Entry Scholarship and a University of New South Wales Australian Postgraduate Award. ZE has received research and travel support from Alere and Abbott.